Michel Mendler is a Gastroenterology physician affiliated with California Liver Research Institute. OpenAlex indexes 56 publications with 1,762 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11370 Anderson St
Stge 3150
Loma Linda, CA 923543450
Telephone
909-558-2191Registry record last updated 8 Jul 2007.
Clinical trials
- Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
Sponsor: Loma Linda University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
- Salix Pharmaceuticals, a division of Bausch Health US, LLCProgram year20241 payment
- Gilead Sciences, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.2%Calcineurin inhibitor62.2%Tacrolimus100%Part D≥11 patientsCardiovascular
20%Loop diuretic20%Furosemide100%Part D<11 patientsAnti-infectives
17.8%Nucleoside and nucleotide reverse transcriptase inhibitors17.8%Vemlidy100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2006 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Characteristics of Metabolic Dysfunction Steatotic Liver Disease in Asian-American Patients with Chronic Hepatitis B
Journal of Immigrant and Minority Health
2026 - Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy
Clinical Journal of Gastroenterology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”